Figure 1
A: Schematic diagram of the TAS strategy. First copy of a cell-specific promoter was used to drive expression of a strong recombinant transactivator, for example GAL4BDp65 fusion protein which consisted of a part of the transcriptional activation domain of the NF-κB p65 protein fused to the DNA-binding domain of GAL4 protein from yeast. The GAL4BDp65 protein then interact with the unique GAL4 binding sequences upstream of the second copy of the cell-specific promoter leading to transactivation of the gene of interest and thus an enhancement of transcription. B: Layout of the lentiviral vectors used in this study. Abbreviations: LTR, lentiviral long terminal repeat; SYN, human synapsin 1 promoter (470 bp); GfaABC1D, a compact glial fibrillary acidic protein promoter (690 bp); mCMV, minimal CMV core promoter (65 bp); GAL4BDp65, a chimeric transactivator consisting of a part of the transactivation domain of the murine NF-κBp65 protein fused to the DNA binding domain of GAL4 protein from yeast; EGFP, enhanced green fluorescent protein; WPRE, woodchuck hepatitis post-transcriptional regulatory element.